🎙️ In this episode we discuss: 01:06 The founding story of Retina AI 03:56 Why ophthalmology is uniquely suited for AI solutions 06:27 Recent Series B funding and what it means for the company 08:31 How AI integrates into real-world clinical workflows 12:04 AI alerts and notifications for clinical decision support 16:36 Working with pharmaceutical companies on clinical trials 19:15 Predicting disease progression for untreated patients 25:42 The transition from traditional AI to newer approaches...
May 01, 2025•39 min•Ep. 139
Chapters 00:00 Introduction and Company Updates 02:49 The Digital Transformation of Ultrasound Imaging 06:00 Advancements in Technology and Market Growth 09:03 AI Integration in Medical Imaging 14:50 Impact on Global Health and Humanitarian Efforts 20:55 Challenges in Mainstream Adoption of Handheld Ultrasound 29:43 Strategic Sales Approaches in Medical Devices 34:11 Finding Product-Market Fit 36:12 Simplicity in Medical Technology 39:26 Unexpected Use Cases and Market Adoption 45:24 Future Inno...
Apr 15, 2025•51 min•Ep. 138
00:00 Introduction and Overview of Caristo Diagnostics 09:08 The Technology Behind Carry Heart 18:00 Clinical Implications and Risk Assessment 27:27 Actionable Steps for Patients 30:34 Optimizing Cardiovascular Drug Dosing 32:31 AI in Cardiovascular Medicine 33:50 Leveraging Historical Data for Risk Prediction 36:25 AI's Role in Molecular Pathway Analysis 39:03 GLP-1 and Cardiovascular Outcomes 41:56 Targeted Therapies in Cardiovascular Treatment 42:45 Building Trust in New Technologies 49:16 Re...
Apr 01, 2025•56 min•Ep. 137
In this episode of The Harry Glorikian Show, host Harry Glorikian welcomes back Jeff Elton, CEO of Concert AI, to discuss the latest advancements in AI-driven healthcare solutions. They reflect on the recent JP Morgan Healthcare Conference, highlighting the optimism surrounding AI's role in transforming drug development and oncology. Jeff shares insights into Concert AI's innovative data ecosystems, partnerships, and the introduction of Kera, an AI platform designed to enhance clinical decision-...
Feb 11, 2025•57 min•Ep. 136
Harry's guest this week is Raffi Krikorian, chief technology officer and managing director at Emerson Collective, the social change organization founded by Laurene Powell Jobs. Krikorian is the former vice president of engineering at Twitter (now X), where he was responsible for getting rid of the Fail Whale and making the company’s backend infrastructure more reliable; the former director of Uber's Advanced Technology Center in Pittsburgh, where he oversaw the launch of the world's first fleet ...
Apr 09, 2024•59 min•Ep. 135
Generative AI is going to change how we do things across the entire economy, including the fields Harry covers on the show, namely healthcare delivery, drug discovery, and drug development. But we’re still just starting to figure out exactly how it’s going to change things. For example, AI is already speeding up the process of discovering new biological targets for drugs and designing molecules to hit those targets—but whether that will actually lead to better medicines, or create a new generati...
Mar 26, 2024•1 hr 3 min•Ep. 134
If you learned that radiologists looking at CT scans for the traditional signs of coronary artery disease catch only 20 percent of the people who actually have a high risk of a heart attack, and if you learned that there’s a new AI-based test that can catch subtle signs of inflammation in the other 80 percent of patients—well, you’d probably want to get that test yourself, right? Harry's guests this week, Frank Cheng and Keith Channon, are from a UK-based company that has developed just such a t...
Mar 12, 2024•1 hr 4 min•Ep. 133
Investors and companies in the life science industry have been betting a lot of money over the last few years on a single idea: that computation will help us get a lot better at developing new drugs. But the word “computation” covers a pretty broad range of techniques. And the reason that there are dozens if not hundreds of computational drug discovery startups popping up is that everyone has their own hypothesis about what specific kind of computation is going to be the most powerful. For examp...
Feb 27, 2024•51 min•Ep. 132
If you look back at all the health-tech and drug development companies Harry has hosted on the show, an interesting pattern starts to emerge: a very large number of those companies have gone on to enormous growth and success in their markets. It could be that being on the podcast is like a catapult to success—or it could be that we're pretty good at finding companies that are already on a promising trajectory. Either way, there's no better example than Concert AI. The company’s CEO, Jeff Elton, ...
Jan 30, 2024•1 hr•Ep. 131
One of the most amazing successes in the battle against cancer over the last two decades has been the introduction of antibody drugs that harness the body’s own immune system to kill tumor cells. Finding those drugs may sound like a biology problem rather than a machine learning or a big-data problem. But actually, these days, it’s both. Harry's guest this week is Leonard Wossnig, who’s the chief technology officer for a UK company called LabGenius. The company uses a combination of synthetic bi...
Jan 16, 2024•38 min•Ep. 130
The combination of better data and more powerful computing is helping researchers reinvent the process of discovering new drugs. Within 5-10 years, we’ll likely see a huge wave of new medicines that were either discovered or designed using AI—drugs that will finally help us get control of our most stubborn health problems, from cancer to cardiovascular disease to obesity and metabolic disorders to neurodegenerative diseases. And the biotech startups that will do most to contribute are the ones t...
Dec 19, 2023•58 min•Ep. 129
There are about 30 trillion human cells in your body, but there are about 38 trillion bacterial cells, mostly hanging out in your large intestine. And that’s not even counting all the viruses, fungi, protists, and other microbial cells that live on your skin, in your bloodstream, and all around your body. So in effect, what you think of as you is not really you. You’re actually a walking colony of many different organisms. All of which cooperate peacefully, for the most part—unless the balance g...
Dec 05, 2023•54 min•Ep. 128
Quality control is one of those things that only a select few people pay attention to—until something goes wrong, then everyone cares. That's especially true in the drug manufacturing industry, where episodes like cross-contamination in a drug factory can shut down a production line and create instant shortages of important medicines. And if a contaminated medicines ever does get shipped out to clinics or stores, people’s lives can be at stake. So drug makers are usually pretty receptive toward ...
Nov 21, 2023•45 min•Ep. 127
There’s a lot of talk out there about how artificial intelligence will change the way doctors and nurses take care of patients; you hear some of it right here on this show. But all of that still feels like a forecast rather than a present reality. When you look really closely, it’s hard to find concrete examples where AI is already helping healthcare providers make better decisions that improve patient outcomes and take costs out of the system. That’s why Harry wanted to have Nassib Chamoun on t...
Nov 07, 2023•1 hr 13 min•Ep. 126
There’s a good chance that we’re all going to live a lot longer than we think. Or at least, that’s what Harry's guest Sergey Young argues in his book The Science and Technology of Growing Young . Young is an investor who leads a $100 million venture capital fund called the Longevity Vision Fund, and through his investing, he says he meets innovators who are coming up with the technologies that will extend our healthy lifespans not just by years but by decades. Those technologies include better d...
Oct 24, 2023•58 min•Ep. 125
It's practically the theme of our show that AI is going to change almost everything about the way drugs get developed and the way healthcare gets delivered. But there’s probably nobody better placed to see how this transformation is already happening than Harry's guest this week, Scott Penberthy. Scott works at Google Cloud, where he’s the director of Applied AI in the Office of the CTO. He and his team work with Google’s big corporate customers, including a variety of customers in healthcare an...
Oct 10, 2023•1 hr 20 min•Ep. 123
Building any kind of startup is hard. Starting a business in healthcare or medical technology is even more challenging, given the long timelines for product development and all the regulatory requirements companies have to meet. But imagine how much harder it would be to start a company if you were still just a senior in high school! Recently Harry learned about a company called Vytal that’s building eye-tracking technology to measure brain health, and he knew he wanted to have the co-founders o...
Sep 26, 2023•40 min•Ep. 124
If you’re looking for help thinking about the implications of exponential change in all areas of technology, one of the best people you can turn to is Azeem Azhar. He's a writer, entrepreneur, and investor who publishes the incredibly popular and influential Substack newsletter Exponential View, which takes deep dives into AI and other subjects with world experts. In 2021 Azeem published a whole book along the same lines called The Exponential Age: How Accelerating Technology is Transforming Bus...
Sep 12, 2023•56 min•Ep. 122
It’s been less than a year since OpenAI opened up ChatGPT to the general public, and less than six months since OpenAI introduced GPT-4, the large language model that currently powers ChatGPT. But in that brief time, the new crop of generative AI tools from OpenAI and competitors like Google and Anthropic has already started to transform the way we think about managing information. We’re entering an era when machines can generate, organize, and access information with a level of accuracy, speed,...
Aug 29, 2023•50 min•Ep. 121
Harry's guest this week is Joe DeVivo, the new CEO of Butterfly Network. The company's goal is to make it radically easier for doctors or medical technicians to perform an ultrasound exam on any part of the body, and radically cheaper for a patient to get one. The companyt makes an FDA-cleared, handheld ultrasound scanner called the Butterfly iQ. The first big thing that’s different about the iQ is that it uses silicon-based microelectromechanical sensors, instead of a traditional piezoelectric ...
Aug 15, 2023•54 min•Ep. 120
This week Harry's guest is....Harry! We're flipping the script and giving Harry a chance to wax eloquent about AI in healthcare and drug research, the growing role of personal health monitoring devices, the unique features of the Boston life science ecosystem, the meaning of the recent downturn in biotech investment, the most common mistakes made by new entrepreneurs, and much more. This week's guest interviewer is Wade Roush, who hosts the tech-and-culture podcast Soonish and has been the behin...
Aug 01, 2023•1 hr 5 min•Ep. 119
Harry's guest this week is Dr. Isaac Kohane, chair of the Department of Biomedical Informatics at Harvard Medical School and co-author of the new book The AI Revolution in Medicine: GPT-4 and Beyond . Large language models such as GPT-4 are obviously starting to change industries like search, advertising, and customer service—but Dr. Kohane says they're also quickly becoming indispensable reference tools and office helpmates for doctors. It's easy to see why, since GPT-4 and its ilk can offer hi...
Jul 18, 2023•58 min•Ep. 118
In the same way that written English is built around an alphabet of just 26 letters, all life on Earth is built around a standard set of just 20 amino acids, which are the building blocks of all proteins. And just as we've invented special characters like emoji to go beyond our standard letters, it turns out that biologists can expand their repertoire of powers using non-standard amino acids—those that either occur rarely in nature, or that can only be made in the lab. GRO Biosciences, a spinout...
Jul 05, 2023•1 hr•Ep. 117
Owning a dog can be a joy, but one sad downside is that dogs are highly prone to cancer—six million of them are diagnosed with the disease in the U.S. each year. Harry's guest this week, Christina Lopes, is co-founder and CEO of a company called One Health that's working to improve cancer outcomes for our canine friends. The company offers a precision cancer diagnosis and treatment service called FidoCure that takes what we’ve learned about genomic testing of tumors in humans and uses it in vete...
Jun 20, 2023•1 hr 2 min•Ep. 116
Unlike cancer, brain diseases like epilepsy, Alzheimer’s disease, or depression don't tend to have easily measured biomarkers that could help doctors tailor treatments, or that could help researchers develop more effective drugs. So in neurology and psychiatry, the precision medicine revolution hasn't really arrived yet. But Beacon Biosignals, where Harry's guest Jacob Donoghue is the co-founder and CEO, is trying to change all that. Beacon is focused on making electroencephalography into a more...
Jun 06, 2023•43 min•Ep. 115
Large language models are already changing the business of search. But now they’re about to change the practice of medicine. Harry's guests, Vivek Natarajan and Shek Azizi, are both researchers on the Health AI team at Google, where they're pushing the boundaries of what large language models can achieve in specialized domains like health. This spring their team announced it would start rolling out a new large language model called Med-PaLM 2 that’s designed to answer medical questions with high...
May 23, 2023•1 hr 1 min•Ep. 114
Harry's guests this week are Sri Kosaraju, the CEO of Inscripta, and Richard Fox, a former Inscripta scientist who just rejoined the company as its SVP of Synthetic Biology. In reabsorbing Infinome—the Inscripta spinout Fox described to Harry in a spring 2021 episode of the show—Inscripta is placing a big bet on biomanufacturing, the creation and fermentation of genetically customized microbes that can pump out medical, agricultural, and nutraceutical products, and more. Inscripta had previously...
May 09, 2023•55 min•Ep. 113
Harry's guest this week, Jen Nwankwo, is the founder and CEO of a drug discovery company in Boston called 1910 Genetics. Her PhD is in pharmacology, which shows through in her practical focus on fixing the drug discovery process to get more and better therapies into the hands of doctors. To hear Jen tell it, 1910 Genetics is focused on finding the most promising new drug candidates for stubborn health problems—and it takes a refreshingly agnostic approach to everything else. The company doesn’t ...
Apr 25, 2023•49 min•Ep. 112
Tears are a signal of more than just our emotions. The liquid in tears comes from blood plasma, and contains a lot of the same proteins and other biomolecules that circulate in the bloodstream. But what this liquid doesn’t have are a lot of the extra components like antibodies that would get in the way if you were looking for specific biomarkers—such as the low-molecular-weight proteins released as a byproduct of the inflammation around tumors. Harry's guests Anna Daily and Omid Moghadam are fro...
Apr 11, 2023•42 min•Ep. 111
It may feel like generative AI technology suddenly burst onto the scene over the last year or two, with the appearance of text-to-image models like Dall-E and Stable Diffusion, or chatbots like ChatGPT that can churn out astonishingly convincing text thanks to the power of large language models. But in fact, the real work on generative AI has been happening in the background, in small increments, for many years. One demonstration of that comes from Insilico Medicine, where Harry's guest this wee...
Mar 28, 2023•1 hr 29 min•Ep. 110
